Clinical Trial Update: A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating atezolizumab plus bevacizumab versus active surveillance as adjuvant therapy in hepatocellular carcinoma at high risk of recurrence a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-11-18